The U.S. Food and Drug Administration (FDA) on February 11, issued emergency use authorization for a new monoclonal antibody, bebtelovimab, for the treatment of COVID-19. “Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19,” the FDA says.COVID: What is monoclonal antibody treatment?
The U.S. Food and Drug Administration (FDA) on February 11, issued emergency use authorization for a new monoclonal antibody, bebtelovimab, for the treatment of COVID-19. “Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19,” the FDA says.
